John G McHutchison

Summary

Affiliation: Gilead Sciences
Country: USA

Publications

  1. pmc Metaprotein expression modeling for label-free quantitative proteomics
    Joseph E Lucas
    Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA
    BMC Bioinformatics 13:74. 2012
  2. doi request reprint The role of genetic markers in hepatitis C virus therapy: a major step for individualized care
    John G McHutchison
    Gilead Sciences, Foster City, CA, USA
    Liver Int 31:29-35. 2011
  3. ncbi request reprint The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients
    Heather M Patton
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA
    J Hepatol 40:484-90. 2004
  4. ncbi request reprint Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies
    Paul J Pockros
    Division of Gastroenterology Hepatology, Scripps Clinic, La Jolla, CA, USA
    J Hepatol 47:174-82. 2007
  5. ncbi request reprint Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients
    Aesop Cho
    Gilead Sciences, 333 Lakeside Drive, Foster City, California 94044, United States
    J Med Chem 57:1812-25. 2014
  6. pmc Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy
    Evguenia S Svarovskaia
    Gilead Sciences, Inc, Foster City, CA, USA
    J Clin Microbiol 50:3267-74. 2012
  7. doi request reprint Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist
    Uri Lopatin
    Gilead Sciences, Foster City, CA, USA
    Antivir Ther 18:409-18. 2013
  8. ncbi request reprint A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA
    Hepatology 37:1368-74. 2003

Collaborators

  • Paul J Pockros
  • Dorothea Sauer
  • Adrian S Ray
  • Ting Wang
  • Polina German
  • Lijun Zhang
  • G Mani Subramanian
  • Evguenia S Svarovskaia
  • Michael D Miller
  • Robert L Carithers
  • Hongmei Mo
  • Aesop Cho
  • Uri Lopatin
  • Joseph E Lucas
  • Keyur Patel
  • Heather M Patton
  • Jason Perry
  • Vangelis Aktoudianakis
  • Anne C Carey
  • Daniel Byun
  • Darius Babusis
  • Thomas Butler
  • Willard Lew
  • Rick Lee
  • Michael Clarke
  • Martijn Fenaux
  • Hong Ye
  • Edward Doerffler
  • Stephen Rossi
  • Jie Xu
  • Weidong Zhong
  • Choung U Kim
  • Joy Feng
  • Sammy Metobo
  • Brian Kearney
  • Grushenka Wolfgang
  • Carol Ohmstede
  • Lisa Moorehead
  • Daniel Tumas
  • Christian R Frey
  • Joseph Hesselgesser
  • M Arthur Moseley
  • Norah Shire
  • Francisco Dieguez
  • Laura G DuBois
  • Phyllis Goldman
  • Jeanette McCarthy
  • J Will Thompson
  • Alexander Thompson
  • Hans Tillmann
  • Ron Hendrickson
  • Kathleen Schwarz
  • Andrew Conrad
  • Lawrence M Blatt
  • Shanon Heaton
  • David Bylund
  • Cynthia Behling
  • Marc Vallee

Detail Information

Publications8

  1. pmc Metaprotein expression modeling for label-free quantitative proteomics
    Joseph E Lucas
    Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA
    BMC Bioinformatics 13:74. 2012
    ..Additionally, there may be systematic shifts in the sensitivity of the machine between experiments or even through time within the duration of a single experiment...
  2. doi request reprint The role of genetic markers in hepatitis C virus therapy: a major step for individualized care
    John G McHutchison
    Gilead Sciences, Foster City, CA, USA
    Liver Int 31:29-35. 2011
    ..They also provide the framework and potential for a clinically relevant and meaningful pharmacogenomic approach to personalizing anti-HCV treatment...
  3. ncbi request reprint The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients
    Heather M Patton
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA
    J Hepatol 40:484-90. 2004
    ..Questions remain regarding the etiology of steatosis in hepatitis C, and its impact on disease progression and treatment outcomes...
  4. ncbi request reprint Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies
    Paul J Pockros
    Division of Gastroenterology Hepatology, Scripps Clinic, La Jolla, CA, USA
    J Hepatol 47:174-82. 2007
    ..To explore safety, pharmacokinetics, and pharmacodynamics of oral administration of resiquimod, a Toll-like receptor 7 and 8 agonist that induces endogenous interferon-alpha, in subjects with chronic hepatitis C virus infection...
  5. ncbi request reprint Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients
    Aesop Cho
    Gilead Sciences, 333 Lakeside Drive, Foster City, California 94044, United States
    J Med Chem 57:1812-25. 2014
    ..In a phase I clinical study, the potential for potent activity was demonstrated but with high intra- and interpatient pharmacokinetic and pharmacodynamic variability. ..
  6. pmc Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy
    Evguenia S Svarovskaia
    Gilead Sciences, Inc, Foster City, CA, USA
    J Clin Microbiol 50:3267-74. 2012
    ..6 to 3.8 log(10) with NS3 protease inhibitor monotherapy that does not suppress the identified preexisting NS3 DRMs and thus a need for a combination therapy...
  7. doi request reprint Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist
    Uri Lopatin
    Gilead Sciences, Foster City, CA, USA
    Antivir Ther 18:409-18. 2013
    ..The aim of this double-blind, placebo-controlled, single ascending-dose study was to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GS-9620 in healthy volunteers...
  8. ncbi request reprint A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA
    Hepatology 37:1368-74. 2003
    ..In conclusion, IL-12 as monotherapy at the doses used in this trial for chronic hepatitis C has low efficacy, was poorly tolerated, and is unlikely to provide an alternative to conventional IFN-based therapy...